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ABSTRACT
Background Skin autofluorescence (SAF) is a noninvasive marker of advanced glycation end products (AGEs).
In diabetes, higher SAF levels have been positively associated with long-term complications, cardiovascular
morbidity and mortality. Because little is known about the factors that influence SAF in nondiabetic individuals,
we assessed the association of clinical and lifestyle parameters with SAF as well as their interactions in a large-
scale, nondiabetic population and performed the same analysis in a type 2 diabetic subgroup.
Methods In a cross-sectional study in participants from the LifeLines Cohort Study, extensive clinical and
biochemical phenotyping, including SAF measurement, was assessed in 9009 subjects of whom 314 (35%)
subjects with type 2 diabetes.
Results Mean SAF was 204  044 arbitrary units (AU) in nondiabetic individuals and 244  055 AU in type 2
diabetic subjects (P < 00001). Multivariate backward regression analysis showed that in the nondiabetic pop-
ulation, SAF was significantly and independently associated with age, BMI, HbA1c, creatinine clearance, genetic
polymorphism in NAT2 (rs4921914), current smoking, pack-years of smoking and coffee consumption. In the
type 2 diabetic group, a similar set of factors was associated with SAF, except for coffee consumption.
Conclusions In addition to the established literature on type 2 diabetes, we have demonstrated that SAF levels
are associated with several clinical and lifestyle factors in the nondiabetic population. These parameters should
be taken into consideration when using SAF as a screening or prediction tool for populations at risk for car-
diovascular disease and diabetes.
Keywords Advanced glycation end products, aging, cardiovascular disease, determinants, skin autofluores-
cence, type 2 diabetes.
Eur J Clin Invest 2016; 46 (5): 481–490
Introduction
Accumulation of advanced glycation end products (AGEs) is
one of the pathophysiological mechanisms associated with
ageing [1]. The formation and accumulation of AGEs is
increased in age-related diseases such as diabetes [2], renal
insufficiency [3] and dementia [4]. AGEs are formed when
proteins are chemically modified by reducing sugars [5] or by
reactive carbonyl compounds [6] and represent cumulative
exposure to metabolic and oxidative stress [7]. Skin autofluo-
rescence (SAF) is a marker for AGE accumulation in the body
and can be assessed noninvasively with a device known as the
AGE Reader.
It has been demonstrated that SAF predicts cardiovascular
morbidity and mortality in diabetes and end-stage renal failure
[8–10]. Furthermore, higher SAF levels have been reported to be
associated with carotid artery intima media thickness [11] and
peripheral artery disease [12,13], independent of diabetes and
renal failure.
SAF may be influenced by both clinical and lifestyle fac-
tors. Previous studies have shown that smokers have higher
SAF levels compared to nonsmokers [9,14] as tobacco smoke
causes oxidative stress and is an exogenous source of reactive
glycation products [15]. Recently, caffeine consumption was
found to be associated with higher skin intrinsic fluorescence
Prior presentations: Parts of this study were presented in the abstract
form at the American Diabetes Association (ADA), June 2014, San
Francisco (USA), and at the European Association for the Study of
Diabetes (EASD), September 2014, Vienna (Austria).
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(SIF) levels in type 1 diabetes [16]. However, more research is
needed to determine whether this association also exists in
nondiabetic and type 2 diabetic subjects. From a genetic
perspective, we have shown a strong association between
N-acetyltransferase 2 (NAT2) acetylator polymorphism
and SAF both in subjects with type 1 and 2 diabetes and
in those without diabetes [17]. These findings demon-
strate that genetic variation is an important modulator of
SAF.
It is important to determine whether SAF is a predictor of
cardiovascular morbidity in an ageing population not affected
by diabetes or renal disease. However, data about factors that
influence SAF in nondiabetic individuals are scarce.
Therefore, we assessed the association between several clin-
ical and lifestyle factors and SAF, along with their interactions
in a large-scale, nondiabetic population, and performed the




Subjects included were participants from the LifeLines Cohort
Study [18], a large prospective population-based cohort study
examining the interaction between genetic and environmental
factors in the development of chronic diseases and healthy
ageing. Between 2006 and 2013, individuals from the northern
region of the Netherlands were invited to participate in the
study through their general practitioner. Baseline data includ-
ing physical examination and extensive questionnaires have
been collected from more than 167 000 participants. Follow-up
visits are scheduled every five years to collect information on
biochemical measures, lifestyle behaviour and psychological
factors contributing to health and disease [19]. All participants
provided written informed consent before participating in the
study. The study has been approved by the Medical Ethical
Review Committee of the University Medical Center Gronin-
gen.
For the current analysis, we evaluated participants
18–80 years of age, from whom SAF measurements and
genetic data were available. This is the same LifeLines
cohort sample as in our previous study on the NAT2 poly-
morphism [17]. We have excluded subjects with type 1 dia-
betes (n = 12) and with severely impaired renal function,
defined as serum creatinine >140 lmol/L (n = 29). This
resulted in 9009 subjects for analysis of whom 314 (35%) had
type 2 diabetes. Of the latter subjects, 212 were already
known to have diabetes and another 102 were newly diag-
nosed by a single fasting blood plasma glucose level
(≥70 mmol/L) at their baseline visit at the LifeLines research
site.
Skin autofluorescence
Skin autofluorescence (SAF) was assessed using the AGE
Reader (DiagnOptics Technologies BV, Groningen, the
Netherlands). This method has been described in detail previ-
ously [14,20]. In short, the AGE Reader illuminates a skin sur-
face of approximately 4 cm², guarded against surrounding
light, with an excitation light source whose wavelength is
between 300 and 420 nm (peak intensity at ~ 370 nm). Emission
light and reflected excitation light from the skin are measured
with an internal spectrometer in the range 300–600 nm. Mea-
surements were taken on the volar side of the forearm, 10 cm
below the elbow, at room temperature. SAF was calculated by
dividing the average emitted light intensity per nanometre in
the range of 420–600 nm by the average excited light intensity
per nanometre in the range 300–420 nm and multiplied by 100.
SAF levels are expressed in arbitrary units and will increase or
decrease per arbitrary unit (AU).
Clinical and lifestyle data
The following clinical datawere collected: age, gender, bodymass
index (BMI), systolic and diastolic blood pressures, serum lipids,
HbA1c, diabetes duration, creatinine clearance and use of medi-
cation. Participants were asked to complete an extensive ques-
tionnaire which included structured questions about smoking
behaviour and coffee consumption. Subjects were classified
according to smoking status at baseline as never smoker, ex-smo-
ker or current smoker. Coffee consumption was recorded as the
number of cups of coffee per day.Wewere not able to distinguish
between caffeinated and decaffeinated coffee consumption.
Anthropometry
Weight was measured to the nearest 01 kg and height to the
nearest 05 cm by trained technicians using calibrated mea-
suring equipment, with participants wearing light clothing and
no shoes. Body mass index (BMI) was calculated as weight
divided by height-squared (kg/m²). Systolic and diastolic blood
pressures were measured every minute for 10 minutes using an
automated Dinamap Monitor (GE Healthcare, Freiburg, Ger-
many). The average of the last three readings was recorded for
each blood pressure parameter.
Biochemical measures and genotyping
Blood was collected in the fasting state between 800 and 1000
a.m. and transported to the LifeLines laboratory facility at room
temperature or at 4 °C, depending on the sample requirements.
On the day of collection, HbA1c (EDTA-anticoagulated) was
analysed using a NGSP-certified turbidimetric inhibition
immunoassay on a Cobas Integra 800 CTS analyser (Roche
Diagnostics Nederland BV, Almere, the Netherlands). Serum
creatinine was measured on a Roche Modular P chemistry
analyser (Roche, Basel Switzerland), and creatinine clearance
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was calculated with the Cockcroft–Gault formula [21]. Total
and high-density lipoprotein (HDL) cholesterol levels were
measured using an enzymatic colorimetric method, triglyc-
erides using a colorimetric UV method, and low-density
lipoprotein (LDL) cholesterol using an enzymatic method and
also on a Roche Modular P chemistry analyser (Roche, Basel,
Switzerland). Fasting blood glucose was measured using a
hexokinase method.
In the analysis, we included the single nucleotide polymor-
phism (SNP) at the NAT2 locus (rs4921914) which was previ-
ously reported to be associated with SAF [17]. The rs4921914
genotypes were imputed (imputation score 089) after exclusion
of low-quality samples and SNPs before imputation of the data
derived from Illumina CytoSNP-12v2 assay (Illumina, San
Diego, CA, USA). Full details on genotyping platform, quality
control, other filters applied to SNPs, and the imputation are
described elsewhere [17].
Statistical analysis
SPSS (version 22, IBM, Armonk, NY, USA) was used for sta-
tistical analysis. Data are shown as mean  standard deviation
(SD) or median and interquartile range (IQR) in case of non-
normally distributed data. Student’s t-test or Mann–Whitney
U-test was performed to compare groups. SAF Z-scores were
calculated based on the total population to correct for age dif-
ferences. Linear regression analysis were performed to deter-
mine the association between clinical and lifestyle determinants
and SAF. First, a baseline model with only age was assessed.
Next, the other determinants were added separately to that
model to assess their individual contributions. A backward
stepwise method was used including all clinical and lifestyle
determinants to derive a final prediction model for SAF,
including only determinants that remained significant. We
assessed possible effect modification between clinical and life-
style factors in their effect on SAF which is shown in a final
interaction model including only significant determinants. To
determine whether associations for SAF differed between sub-
jects with and without diabetes, we additionally tested for the
interaction between diabetes and clinical and lifestyle factors. A
final prediction model for the total population was assessed
including significant determinants only. P < 005 (two-tailed)
was considered statistically significant.
Results
Table 1 provides the clinical characteristics of the study popu-
lation. Mean age of the nondiabetic population was 49 years,
10 years younger than the type 2 diabetic subgroup
(P < 00001). SAF levels were significantly higher in the type 2
diabetic population (244  055 AU) than in the nondiabetic
subgroup (204  044 AU) (P < 00001).
Table 1 Clinical characteristics of the non-diabetic population
and type 2 diabetic group
Parameters Non-diabetes Type 2 diabetes
N 8695 314
Age (years) 49  11 59  11**




Body mass index (kg/m²) 264  42 305  54**
Systolic blood pressure
(mmHg)
129  16 137  17*
Diastolic blood pressure
(mmHg)
75  9 77  9
Total cholesterol (mmol/L) 51  09 47  12
HDL cholesterol (mmol/L) 14  04 12  03
LDL cholesterol (mmol/L) 33  09 29  10
Triglycerides (mmol/L) 105 (08–15) 141 (10–14)
Creatinine clearance (mL/min) 113  31 119  45*
HbA1c (%) 55  03 68  12**




Oral agents/insulin, % n.a. 47/15†
Statins, % 62 462**
NAT2 polymorphism, n (%)
TT 5685 (65) 209 (67)
CT 2706 (31) 96 (30)
CC 304 (4) 9 (3)
Smoking status, n (%)‡
Never smokers 3508 (41) 106 (34)
Ex-smokers 3174 (37) 147 (48)
Current smokers 1914 (22) 56 (18)
Pack-years in ex- and current
smokers
11 (46–190) 18 (85–294)*
Coffee consumption (cups
per day)
38 (23–52) 38 (19–55)
SAF (AU) 204  044 244  055**
SAF, skin autofluorescence; AU, arbitrary units.
Data are presented as means  standard deviation, or median (interquartile
range) and number (%). Creatinine clearance (Cockcroft–Gault formula).
†Twenty-nine subjects used oral agents + insulin.
‡Missing values for smoking status (n = 104).
*P < 0001 **P < 00001.
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Univariate associations with SAF
The univariate associations between clinical and lifestyle
determinants and SAF showed that in the nondiabetic popu-
lation, age, male gender, BMI, HbA1c, total cholesterol, LDL
cholesterol, triglycerides, current smoking, ex-smoking, pack-
years of smoking and coffee consumption were positively
associated with SAF (Table S1).
Negative associations were found for creatinine clearance
and the fast acetylator allele of NAT2. In the type 2 diabetic
group, age, HbA1c, current smoking, pack-years of smoking
and coffee consumption were positively associated with SAF.
Creatinine clearance, total cholesterol, LDL cholesterol and the
fast acetylator allele of NAT2 were negatively associated with
SAF (Table S1).
Multivariate associations with SAF
A baseline model including age explained 285% of the
variance in SAF in the nondiabetic population (Table 2).
Pack-years of smoking (40%), current smoking (37%), coffee
consumption (36%) and NAT2 polymorphism (21%) had the
highest additional contribution. In the type 2 diabetic
population, 238% of the variance in SAF could be explained
by age. Current smoking had the highest additional
contribution (89%) to the baseline model, followed by
pack-years of smoking (44%) and NAT2 polymorphism
(27%).
In the nondiabetic population, the multivariate regression
model showed that age, BMI, HbA1c, creatinine clearance,
NAT2 polymorphism, current smoking, pack-years of smok-
ing and coffee consumption were independent predictors of
SAF explaining 338% of the variance in SAF (Table 3). In the
type 2 diabetic population, a similar set of predictors
excluding coffee consumption explained 468% of the vari-
ance in SAF.
The effect of coffee consumption on SAF
In the nondiabetic population, coffee consumption was sig-
nificantly and dose-dependently associated with higher SAF
Z-scores (P < 0001), whereas for the type 2 diabetic popula-
tion a nonsignificant trend was found (P = 0104) (Fig. 1). The
association between coffee consumption and SAF was modi-
fied by NAT2 polymorphism (P = 0001) (Table S2). Among
subjects having a TT genotype, a mean intake of one cup of
coffee per day was associated with 0052 AU increase in SAF
(0032 AU and 0029 AU for CT, respectively, CC genotype)
(Table S3). In the type 2 diabetic population, a mean intake
of one cup of coffee per day was associated with 0049
AU increase among subjects with a TT genotype. The asso-
ciations for CT genotype (0016 AU) and CC genotype
(0005 AU) were not significant (P = 0380 and P = 0948,
respectively).
Smoking and SAF
Figure 2 shows the age-adjusted SAF Z-scores for different
smoking groups. Within each smoking group, subjects from
the nondiabetic population had significantly lower SAF
Z-scores compared to subjects with type 2 diabetes (never
smokers, P < 005; ex-smokers, P < 00001; current smokers,
P < 00001). In both groups, current and ex-smokers had
higher SAF Z-scores compared to never smokers (P < 005 –
P < 00001).
Furthermore, SAF levels increased with the number of
pack-years smoked, indicating a dose-dependent effect
(Fig. S1).
Clinical and lifestyle interactions
Next, we evaluated effect modification for clinical and lifestyle
determinants in their effect on SAF. A significant interaction
between current smoking and age (P < 00001) was observed
showing that one-year increase in age was associated with an
additional 0002 AU increase in SAF, which implies a 12%
increase in age dependency (data not shown). The final inter-
action model for the nondiabetic population, including signifi-
cant determinants only, is presented in Table S2.
Finally, we assessed whether associations with SAF differed
between subjects with and without diabetes. Effect modifica-
tion was observed for type 2 diabetes and HbA1c (P < 00001)
(data not shown) with HbA1c having a larger effect on SAF in
subjects with type 2 diabetes compared to individuals without
diabetes. Also, a significant interaction between current smok-
ing and type 2 diabetes (P = 004) in their association with SAF
was found (data not shown). Current smoking had a larger
effect on SAF in subjects with type 2 diabetes compared to
nondiabetic individuals which was already demonstrated in
Table 2 and Fig. 2. The final prediction model for SAF for the
total population is given in Table S4.
Discussion
This is the first study to report an integrated analysis of both
lifestyle and clinical factors that influence SAF in a large-scale
nondiabetic population as well as in a subpopulation with type
2 diabetes. We have shown that SAF is significantly and inde-
pendently associated with age, BMI, HbA1c, creatinine clear-
ance, NAT2 polymorphism, current smoking, pack-years of
smoking and coffee consumption explaining 338% of the
variance in SAF. In the type 2 diabetic population, SAF was
associated with the same factors with the exception of coffee
consumption and explained 468% of the variance in SAF.
Coffee consumption was dose-dependently associated with
higher SAF levels both in the nondiabetic population and in
subgroup of type 2 diabetic individuals. Recently, Eny et. al.
reported a positive association between caffeine consumption
484 ª 2016 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd
on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
R. P. VAN WAATERINGE ET AL. www.ejci-online.com
Table 2 Multivariate linear regression model for skin autofluorescence (SAF) in the non-diabetic population and type 2 diabetic group
Determinants Coefficient b SE P Value R2 (%)
Non-diabetes (N = 8695)
Baseline model
Age 0021 36 9 10 4 10 9 10 200 285
Clinical and lifestyle parameters DR2 (%)
Male gender 0053 0008 41 9 10 11 04
Body mass index 0004 0001 15 9 10 4 01
HbA1c 0082 0014 32 9 10 9 03
Creatinine clearance (mL/min) 20 9 10 4 31 9 10 4 32 9 10 8 03
Total cholesterol 0001 0004 0893 00
LDL cholesterol 0004 0005 0396 00
HDL cholesterol 0084 0010 67 9 10 16 05
Triglycerides 0030 0005 25 9 10 9 03
NAT2 polymorphism (CC vs. CT and TT) 0114 0007 12 9 10 57 21
Current smoking vs. never smoking 0205 0009 54 9 10 101 37
Ex-smoking vs. never smoking 0029 0009 0001 01
Pack-years 0007 46 9 10 4 42 9 10 56 40
Coffee consumption (cups per day) 0076 0002 36 9 10 108 36
Type 2 diabetes (N = 314)
Baseline model
Age 0025 0003 38 9 10 20 238
Clinical and lifestyle parameters DR2 (%)
Male gender 0151 0054 0005 19
Body mass index 0003 0005 0589 01
HbA1c 0064 0023 0006 18
Creatinine clearance (mL/min) 0005 0002 0011 16
Total cholesterol 0063 0023 0007 18
LDL cholesterol 0072 0026 0006 16
HDL cholesterol 0250 0086 0004 18
Triglycerides 0036 0021 0087 05
Estimated diabetes duration 0005 0004 0246 06
NAT2 polymorphism (CC vs. CT and TT) 0167 0050 0001 27
Current smoking vs. never smoking 0436 0069 70 9 10 10 89
Ex-smoking vs. never smoking 0032 0056 0570 01
Pack-years 0006 0002 0001 44
Coffee consumption (cups per day) 0029 0012 0018 16
NAT2, N-acetyltransferase 2; SE, standard error; R2: explained variance in SAF (%); DR2: additional explained variance of clinical and lifestyle parameters on top
of baseline model.
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and SIF in type 1 diabetes [16]. However, a previous Dutch
study examining the association between dietary habits and
SAF found no association between coffee consumption and SAF
among 147 elderly subjects [22]. The average amount of coffee
consumed daily was comparable to our study (mean 34 cups
compared to a median of 38 cups); but, the subjects in our
study were on average 10 years younger. Another –more likely
– explanation for the different findings might be that their
study was underpowered due to the small sample size.
Factors that could explain elevated SAF levels in coffee con-
sumers may be fluorescent substances in coffee (fluorophores)
or indirectly as a consequence of the roasting process of coffee
beans, which can be considered as a Maillard reaction, leading
to the formation of browning products such as melanoidins
[23]. Also, it might be that coffee consumers are more likely to
smoke which would result in a positive association between
coffee consumption and SAF. Nevertheless, we found that both
determinants were independently associated with SAF in the
multivariate model, whereas no effect modification was
observed.
Coffee is one of the most consumed beverages around the
world, and many studies have examined its association with
health and disease. Moderate amounts of coffee consumption
have been reported to be protective against cardiovascular
disease [24] and type 2 diabetes [25,26]. In addition, a recent
study has demonstrated that coffee consumption was associ-
ated with a lower risk of overall mortality [27]. Coffee is a major
source of the phenolic antioxidant chlorogenic acid, and its
daily intake from coffee consumption is estimated to be 05–1 g
[28]. Part of the beneficial effects of coffee consumption might
be attributed to chlorogenic acid which reduces oxidative stress
and inhibits hydrolysis of glucose-6-phosphatase, leading to
lower plasma glucose concentrations [29]. Interestingly,
chlorogenic acid has been reported to inhibit AGE formation
Table 3 Prediction model for skin autofluorescence (SAF) in the non-diabetic population and the type 2 diabetic group
Predictors Coefficient b SE P Value R2 (%)
Non-diabetes (n = 8695)
Age 0018 0001 13 9 10 116 338
Body mass index 0006 0002 0001
HbA1c 0061 0019 0001
Creatinine clearance
(mL/min)
0001 28 9 10 4 79 9 10 7
NAT2 polymorphism
(CC vs. CT and TT)
0119 0009 10 9 1035
Current smoking vs.
never smoking
0115 0013 96 9 10 20
Pack-years 0004 49 9 10 4 70 9 10 20
Coffee consumption
(cups per day)
0032 0002 30 9 10 40
Type 2 diabetes (N = 314)
Age 0017 0006 0004 468
Body mass index 0020 0010 0039










Pack-years 0005 0002 0018
NAT2, N-acetyltransferase 2; SE, standard error; R2: explained variance in SAF (%).
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in vitro [30,31]. During the roasting process of coffee beans
however, a significant amount of chlorogenic acid is lost [32].
Hereby, the inhibitory effect of chlorogenic acid on AGE for-
mation might be attenuated. The roasting process of coffee
beans further leads to profound changes in the chemical com-
position of coffee brew, including the formation of melanoidins
as the end products of the Maillard reaction [23]. This may
explain how coffee consumption, as an exogenous source of
AGE can contribute to increased SAF levels. Overall, the pre-
sent study shows that coffee consumption is associated with
higher SAF levels. When using SAF to predict cardiovascular
events, this may lead to overestimation of true risk in those
with high coffee consumption.
Previously, we have shown that N-acetyltransferase 2
(NAT2) acetylator polymorphism was significantly associated
with SAF [17]. NAT2 is a drug-metabolizing enzyme for which
certain gene polymorphisms have been associated with
increased risk of several cancers [33]. Interestingly, in the pre-
sent study, effect modification was observed for NAT2 poly-
morphism and coffee consumption in their effect on SAF.
The effect of coffee consumption on SAF was strongest for
individuals with the slow acetylator genotype and weakest for
individuals with the fast acetylator genotype. Previous studies
have shown that NAT2 is involved in the metabolic pathway of
caffeine [34,35]. As caffeine has fluorescent properties [36], it
may be that the association between NAT2 and SAF was
influenced by fluorescence of caffeine present in the skin.
However, both NAT2 polymorphism and coffee consumption
were also independently associated with SAF when analysed
together.
Our results showing significantly higher SAF levels in cur-
rent smokers compared to never smokers are in agreement with
earlier studies performed in type 2 diabetes [9,14]. In addition,
a higher number of pack-years was associated with higher SAF
levels, which was also found in a study among patients with
chronic obstructive pulmonary disease [37].
Theoretically, many years of smoking – and thus exposure to
long-term oxidative stress – may contribute either directly or
indirectly to increased accumulation of AGEs throughout
life. As smoking enhances the risk for diabetes-related
Figure 2 Age-adjusted SAF Z-scores stratified for smoking
status in the non-diabetic population and type 2 diabetic group.
Boxes show mean, minimum and maximum SAF Z-scores,
whiskers represent the 5th and 95th percentile. Sample size per
category: non-diabetes, never smoker (n = 3516), type 2
diabetes, never smoker (n = 106); non-diabetes, ex-smoker
(n = 3186), type 2 diabetes, ex-smoker (n = 150); non-diabetes,
current smoker (n = 1919), type 2 diabetes, current smoker
(n = 57). SAF, skin autofluorescence. *P < 005, **P < 00001.Figure 1 The effect of coffee consumption on SAF in the non-
diabetic population and type 2 diabetic group. Dots (type 2
diabetes) and squares (non-diabetes) show mean SAF
Z-scores  SEM, r2 correlation coefficient. Sample size per
category: non-diabetes, 0 cups of coffee per day (n = 563), type
2 diabetes, 0 cups of coffee per day (n = 11); non-diabetes, 1–2
cups of coffee per day (n = 1491), type 2 diabetes, 1–2 cups of
coffee per day (n = 43); non-diabetes, 3–4 cups of coffee per
day (n = 3044), type 2 diabetes, 3–4 cups of coffee per day
(n = 79); non-diabetes, 5–6 cups of coffee per day (n = 2263),
type 2 diabetes, 5–6 cups of coffee per day (n = 63); non-
diabetes, >6 cups of coffee per day (n = 1061), type 2 diabetes,
>6 cups of coffee per day (n = 35). SAF, skin autofluorescence.
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cardiovascular complications [38], it might be that the larger
effect of smoking on SAF in type 2 diabetic subjects translates
into higher cardiovascular risk of smoking in diabetes. Future
follow-up studies are needed to confirm this hypothesis.
As expected, age was significantly and independently asso-
ciated with SAF in both the nondiabetic population and type 2
diabetic subgroup. In general, mean SAF was significantly
higher in the type 2 diabetic subgroup compared to the non-
diabetic population, but it should be emphasized that the for-
mer group was on average 10 years older. Ageing has been
thought to be a key factor in nonenzymatic glycation of proteins
[1,5] which has been confirmed in several studies using the
AGE Reader, all showing a linear relationship between
increasing age and higher SAF [14,20].
The pathway of endogenous AGE formation might be dif-
ferent between subjects with and without diabetes. In diabetes,
AGE formation is based on a combination of chronic hyper-
glycaemia and oxidative stress [6,7] as well as through lipid-
derived intermediates, resulting in advanced lipoxidation end
products (ALEs) [39]. In addition, as serum AGEs are cleared
by the kidney [3], changes in renal function may also influence
AGE accumulation [40]. In subjects without diabetes however,
ageing is thought to be the most important factor contributing
to endogenous AGE formation [1,5], as can be deduced from
our results.
HbA1c, a measure of semi-recent glycaemic status, was sig-
nificantly associated with higher SAF levels, with a larger effect
among type 2 diabetic individuals. A study among type 2 dia-
betic individuals concluded that SAF was poorly predicted by
HbA1c level [41]. In type 1 diabetes, SAF was associated with
long-term mean HbA1c, but not with most recent HbA1c [42].
Another study among Japanese type 1 diabetes patients
showed that SAF significantly correlated with HbA1c over the
past 15 years which probably is a better measure of long-term
glycaemic load [43]. An earlier study showed that Hb-AGE was
a better indicator for long-term blood glucose control compared
to HbA1c [44]. In clinical practice, HbA1c represents the aver-
age glycaemic control over the last 5–6 weeks [44]. HbA1c
levels in diabetes can fluctuate over short-time periods [45],
which makes it plausible that the association with SAF,
reflecting a much longer-term metabolic memory (~ 15 years)
[46], is inconsistent. In nondiabetic subjects, HbA1c levels are
expected to show fewer fluctuations which could explain a
more consistent relationship with SAF in the population with-
out diabetes.
Our study has some strengths and limitations. First, the
large majority of our study population were individuals
without diabetes making this SAF study unique. Moreover,
due to the large number of participants, we were able to
perform analysis for different smoking statuses and the vari-
ety in the amount of coffee consumption typically found in
the general population. Because clinical data were obtained at
the same time of the SAF measurement, the associations found
are highly reliable. A limitation of our study is a potential
misclassification of some individuals with regard to their
smoking status as we cannot rule out misreporting of smoking
habits or history. Secondly, diagnoses of type 2 diabetes were
made by a single fasting plasma glucose only. Unfortunately,
we were not able to include in our analysis the use of other
caffeine-rich beverages, such as tea or soft drinks, or caffeine
from foods.
In addition to the established literature in type 2 diabetes, we
have demonstrated that SAF is influenced by clinical and life-
style factors, including smoking and coffee consumption in a
large-scale nondiabetic population. These parameters need to
be taken into consideration when using SAF as a screening or
prediction tool for populations at risk for cardiovascular dis-
ease and diabetes.
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